The combination of FAK/Pyk2 tyrosine kinase inhibitor (PF‐562,271) and sunitinib could inhibit different aspects of angiogenesis and tumor aggressiveness and it might have better anti‐cancer effect than a relevant single agent in HCC (Bagi et al., 2009). This evidence concerns the gene PTK2B and cancer.